Abstract: The invention relates to a DNA sequence which encodes three specific human cytomegalovirus (HCMV) peptides of the pp150 protein. These peptides are shown to have novel immunogenic properties. The DNA sequence is also used in a method of hybridization for the detection of fully complementary sequences.

Abstract: An apparatus for combining liquid or solid components stored in containers includes a cylindrical hollow body for receiving end closures of the containers and at least one cannula for penetrating the end closures. The cannula is mounted in a cannula holder movable in the hollow body, and retainer bridges connect the cannula holder to an inner wall surface of the hollow body. The retainer bridges fracture after the cannula penetrates the end closure in the first container so that the cannula moves toward the second container to penetrate the closure in the second container.Also disclosed is a system including the apparatus, two containers, and outer packaging enclosing the containers and the hollow body.

Abstract: The invention concerns methods to increase the expression of genes brought into eukaryotic cells or organisms. By flanking a transcription unit EPC made up by e.g. an enhancer (E), promoter (P), and the (structural) gene of interest (C) with attachment-elements (A) the expression of said (structural) gene of interest is stimulated when integrated into the genome of eucaryotic cells and is independent of its chromosomal position. Thus a construct AEPCA is advantageous because it constitutes an independant regulatory unit.

Abstract: The invention relates to monoclonal antibodies of high avidity, which react specifically with the gangliosides GD3 and GQ1b, and to their use for detecting melanomas and other tumors or tissues expressing GD3 and GQ1b.

Abstract: The invention relates to a process for producing a virus free preparation of thrombin, and the use of said virus free concentrate as a pharmaceutical. For example, the invention relates to a process for the production of a purified and virus free preparation of thrombin which comprises adding a soluble salt in a concentration of from 0.5 mol/l up to the saturation limit thereof, said soluble salt having an anion that forms a sparingly-soluble salt or a soluble complex with calcium, to a solution of a prothrombin complex which has been purified on an anion exchanger and subjected to virus inactivation, said solution having a catalytic amount of thrombin present as a result of the purification, the viral inactivation, or added thereafter at a concentration of greater than zero up to 200 units of thrombin per ml of solution.

Abstract: Antibodies which are specific for Saccharomyces cerevisiae, Saccharomyces bayanus, Saccharomyces paradoxus and Saccharomyces pastorianus, and epitopes to which such antibodies bind are described. Diagnostic agents and assays for detecting Saccharomyces sensu strictu and epitopes of Saccharomyces sensu strictu also are described.

Abstract: Erythropoietin (EPO) peptides and the use thereof for preparing epitope-specific anti-EPO antibodies are described. Also described are corresponding anti-EPO antibodies which take the form of polyclonal antibodies (antisera) or of monoclonal antibodies. These antibodies are suitable for purifying EPO, EPO derivatives or EPO peptides. The epitope-specific anti-EPO antibodies according to the invention can also be used for the detection of EPO and, in particular, for the epitope-specific detection of EPO. Additionally described are anti-idiotype antibodies which imitate a receptor region of EPO. Finally, pharmaceuticals which contain the EPO peptides, anti-EPO antibodies or anti-idiotype antibodies, and diagnostic aids for the detection of EPO or of anti-EPO antibodies, are described.

Abstract: The invention relates to a combination of substances (component I) inducing necrosis in tumors or inflamed tissue with other nontoxic substances ("prodrugs", component II). The enzymes set free by necrotic processes then cleave the nontoxic "prodrug" into the toxic "drug", which leads to massive tumor cell death and/or remission of inflammation.

Abstract: Mutants of AT III which have been advantageously modified at one or more potential glycosylation sites or at the Arg393 position are described. As a rule, combination of the mutations enhances the advantageous modifications.

Abstract: The invention relates to fluorogenic compounds for the detection of hydrolyzing enzymes and the use of the fluorogenic compounds.

Abstract: A description is given of the possibility of using transglutaminases in a process for the preparation of an immunosuppressant. Additionally described is a pharmaceutical containing a transglutaminase and a plasminogen activator inhibitor.

Abstract: The invention relates to monoclonal antibodies against a tumor-associated antigen which is mainly derived from tumors from the group of carcinomas of the breast, ovaries and prostate, as well as adenocarcinomas of the lung, which additionally react with polymorphic epithelial mucin (PEM), to the preparation and use thereof and to the use of the epitope defined by the antibody for diagnosis and therapy.

Abstract: Liquid pharmaceuticals for subcutaneous (sc) or intramuscular (im) administration containing a polypeptide and at least one amino acid, a process for the preparation of such a pharmaceutical and the use of an amino acid, which is suitable for sc or im administration, in a solution of a polypeptide are described.

Abstract: A process for the purification of factor XIII or XIIIA by immunoaffinity chromatography, monoclonal antibodies against factor XIIIA, the preparation thereof and the use thereof are described.

Abstract: The invention relates to monoclonal antibodies and parts thereof which bind preferentially to active human platelets, to the nucleotide sequence and amino-acid sequence of the heavy and light chain of MAb BW 2128 and to an antigen associated with thrombospondin.

Abstract: The present invention relates to reagents and processes for the preparation of diagnostics which use a chromogenic redox detection system and whose chromogenic redox detection system essentially remains unaffected by interference from reducing compounds in the sample material.

Abstract: The invention relates to polynucleotides encoding the BW 835 variable domain of an antibody against a tumor-associated antigen which is mainly derived from tumors from the group of carcinomas of the breast, ovaries and prostate, as well as adenocarcinomas of the lung, which additionally react with polymorphic epithelial mucin (PEM), and expression vectors containing the polynucleotides.

Abstract: The invention relates to magnetic protein conjugates of the formula I ##STR1## in which M represents a dispersible magnetically reacting material or particle which carries aminogroups, Ig represents a protein which carries one or more mercapto groups, and X represents an organic chemical structure which links the two ligands by chemical means, to a process for the preparation of protein conjugates of the formula I, and to the use of conjugates of this type for removing cells or soluble bioorganic molecules or components from aqueous salt solutions or body fluids, and to the use thereof within the framework of a diagnostic method or as a diagnostic aid.

Abstract: The invention concerns the transformation of human T-lymphocytes to stable growth by infecting said T-cells with strains of H. saimiri subgroup NonA NonB, preferably subgroup C. The transformed cells grow independently of antigen stimulation and can have a phenotype of activated mature T-lymphocytes, expressing cell surface markers characteristic for the distinct differentiation status of the T-cells. Infection with strains of H. saimiri belonging to the subgroups above can thus be used to generate human T-cell lines for a variety of immunological and biochemical applications as well as for therapeutic use.

Abstract: The invention relates to a skin test to human papillomavirus (HPV) type 16.